The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Silas Inman, OncLive
Advertisement
Articles by Silas Inman, OncLive
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.
Advertisement
Latest Updated Articles
- Pre-Chemo Enzalutamide Approved for Metastatic Castration-Resistant Prostate Cancer
Published: September 11th 2014 | Updated:
FDA Approves Neoadjuvant Pertuzumab RegimenPublished: October 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
4
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
5
